Navigation Links
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
Date:5/8/2008

erations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com

Genta Incorporated

Selected Condensed Consolidated Financial Data

(In thousands, except per share data)

(Unaudited)

Three Months Ended

March 31

2008 2007

Product sales - net $117 $94

Cost of goods sold 25 22

Gross margin 92 72

Operating expenses:

Research and development 6,438 3,383

Selling, general and administrative 3,638 4,052

Provision for settlement of

litigation, net (260) (1,560)

Total operating expenses 9,816 5,8
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... East Longmeadow, MA (PRWEB) September 16, 2014 ... the appointment of Brian Highley as CEO of CIRTEC. ... at this exciting point for the Company.” noted Brian ... and operational performance while sustaining strong organic growth over ... accelerate CIRTEC’s growth by continuing to improve and expand ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... September 16, 2014 Convoy Therapeutics, ... and effective products to treat patients directly at ... a proprietary SPACE™ Technology Platform announced today that ... will present at the White Hat Life Science ... Hyatt Regency Phoenix. In addition, interested individuals ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4
(Date:9/16/2014)... The fire is human-caused and is still under ... and is mostly being fueled by grass and timber. ... to higher humidity. Yesterday (8/15), firefighters made progress ... fireline on the West and North sides of the fire. ... 7 20-person Crews, 4 Hot Shot Crews, 1 large Type ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
(Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... Humans and animals are able to perceive even the ... channels play a crucial role in the mediation of ... membrane which are highly responsive to external signals. Mechanosensitive ... ions (electrically charged particles), to cross the cell membrane, ...
... oil and gas concessions threatens the megadiverse Peruvian Amazon. ... reach around 70% of the region, threatening biodiversity and ... from a pair of researchers from the Institut de ... Barcelona (UAB), and the Washington DC-based NGO Save America,s ...
... and THE HAGUE, The Netherlands -- Recognizing the ... relationship and become recognized research leaders in the ... security, Stevens Institute of Technology recently entered into ... A Memorandum of Understanding (MOU) between the university ...
Cached Biology News:MDC researchers link protein tether to touch perception 2A second hydrocarbon boom threatens the Peruvian Amazon 2A second hydrocarbon boom threatens the Peruvian Amazon 3Stevens and TNO to collaborate on maritime security 2
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... against Nonmuscle Myosin II Heavy Chain ... in TBS + 0.03% Thimerosal) This ... SDVNETQPPQSE corresponding to the C-terminus of ... (MHC-B) This antibody is effective in ...
... reduced and non-reduced forms. It does not react ... XII. Factor XIII is a Beta-globulin found in ... XIII-A is the catalytic subunit and is a ... in plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); ...
... is a fully integrated system for fluorescent ... that deliver excellent quality microarray images. The ... microarray scanner that is based on patented ... rejection and spatial resolution. The DNAscope V ...
Biology Products: